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A ten-year-old female presented to our dermatology clinic with 
her mother, our patient, at which time we incidentally noted a large 
light brown patch on the daughter’s cheek (shown above). The girl 
was a fifth grader in elementary school. On physical exam, a large 
brown smooth patch with jagged borders consistent with a café-
au-lait patch was noted on the right cheek. The lesion was present 
since birth, was asymptomatic, and had grown in proportion with her 
growth overtime. 
The girl noted a history of early menses beginning at the age of 
two for which she follows with endocrinology. She noticed breast 
enlargement at the age of seven years old. She also noted a history 
of multiple bone fractures, most recently of the femur after falling 
in the yard. Musculoskeletal exam revealed asymmetric limb length 
with the left leg longer than the right. She was ambulating on crutches 
after fracturing her femur in a fall. Breast exam revealed large breasts 
relative to height and age. The remainder of the physical exam was 
non-contributory. 
DISCUSSION
Given the clinical manifestations, the patient was diagnosed with 
McCune Albright Syndrome (MAS), a genetic syndrome character-
ized by the clinical triad of polyostotic fibrous dysplasia, endocrine 
abnormalities, most frequently precocious puberty, and a pathog-
nomonic café-au-lait patch.1 The differential diagnosis of MAS is 
neurofibromatosis type 1 (NF1), Cutaneous-Skeletal Hypophosph-
etemia Syndrome, and various fibro-osseous skeletal lesions, such as 
giant cell tumors of bone, ossifying fibromas, osteofibrous dysplasia, 
and cherubism.2 While NF1 shares several features with MAS, such 
as café-au-lait macules and skeletal deformities, the nature of the 
café-au-laits (smaller and more numerous) and skeletal deformities 
(i.e., sphenoid dysplasia and pretibial bowing), along with tumors of 
the nervous system, distinguish it from MAS. Cutaneous-skeletal 
hypophosphatemia syndrome presents with epidermal and con-
genital melanocytic nevi as opposed to café-au-laits and the skeletal 
development abnormalities are usually that of rickets/osteomala-
cia rather than polyostotic fibrous dysplasia. Finally, fibrous skeletal 
lesions, as listed above, are usually solitary and lack the extra-skeletal 
manifestations seen in MAS.
MAS is a genetic syndrome caused by a post-zygotic somatic 
activating mutation in GNAS (guanine nucleotide binding protein, 
alpha stimulating).2 It initially presents with a unique café-au-lait 
patch characterized by a light brown patch with jagged, irregular 
boarders that classically resembles the “coast of Maine”. This lesion 
is typically apparent at or shortly after birth. Often, the café-au-lait 
patch follows the developmental Blaschko lines.2 The second clini-
cal feature is that of an endocrine abnormality. The most common 
endocrine abnormality is precocious puberty seen in approximately 
85% of female patients with MAS.2 Other endocrine abnormalities 
that can occur are hyperthyroidism, growth hormone excess, hyperp-
rolactemia, and hypercortisolism.1 Endocrinopathies typically occur 
in infancy or early childhood and persist into adulthood.3 In a study 
of 11 patients with MAS, the average age of gonadotropin-indepen-
dent precocious puberty onset was around five years with ages of 
onset ranging from two months to eight years.4 Precocious puberty 
in MAS often is referred to as gonadotropin-independent precocious 
puberty (GIPP). Recurrent ovarian cysts result in episodic estrogen 
production and intermittent vaginal bleeding.3 In males, testicular 
involvement is common, but precocious puberty rarely develops.5 
Finally, patients with MAS present with polyostotic fibrous dys-
plasia in which the patient’s normal bone and bone marrow are 
replaced by fibro-osseous tissue, leading to fibrous deposition in 
bones.2 This results in an increase in frequency of bone fractures, 
skeletal deformities, functional impairment, and pain after minimal 
trauma. Clinicians must have a high suspicion for a diagnosis of MAS 
when a patient exhibits two or more clinical features described above. 
Genetic testing for GNAS should be performed to confirm the diag-
nosis.2 Managing the manifestations of MAS should be individualized 
and can be best accomplished by a multidisciplinary team consisting 
of a primary care physician, endocrinologist, orthopedic surgeon, and 
physical therapist, with routine follow-up.2,3,6 Finally, support groups 
such as the MAGIC Foundation and the Fibrous Dysplasia Founda-
tion also are available for patients and their families.6
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